"Sesquiterpenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fifteen-carbon compounds formed from three isoprenoid units with general formula C15H24.
| Descriptor ID |
D012717
|
| MeSH Number(s) |
D02.455.849.765
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sesquiterpenes".
Below are MeSH descriptors whose meaning is more specific than "Sesquiterpenes".
This graph shows the total number of publications written about "Sesquiterpenes" by people in this website by year, and whether "Sesquiterpenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sesquiterpenes" by people in Profiles.
-
Li KM, Ren LY, Zhang YJ, Wu KM, Guo YY. Knockdown of microplitis mediator odorant receptor involved in the sensitive detection of two chemicals. J Chem Ecol. 2012 Mar; 38(3):287-94.
-
Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. Int J Gynecol Cancer. 2010 Oct; 20(7):1137-41.
-
Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, Meng R, Quong AA, Latz E, Scott CP, Alnemri ES. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010 Mar 26; 285(13):9792-802.
-
Schilder RJ, Blessing JA, Pearl ML, Rose PG. Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Invest New Drugs. 2004 Aug; 22(3):343-9.
-
Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol. 2004 Oct; 54(4):308-14.